Is iBio, Inc. (IBIO) a Buy, Sell, or Hold?
NASDAQ : IBIO
iBio, Inc.
$1.41 USD
$0.02 (1.44%)
- Volume
- 435.93K
- Average Volume
- 960.55K
- Market Capitalization
- $22.26M
- P/E Ratio
- -2.45
- Dividend Yield
- 0.00%
- Price Target
- $5.00
- Year High
- $3.82
- Year Low
- $0.57
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $11.88
Company Overview
NASDAQ
Martin Brenner
Biotechnology
Healthcare
IBIO
20
US
USD
Liquidity Metrics
0.03
11.88
11.88
7.32
0.00
Sales & Valuation
$400K
74.21
2.17
-1.00
-0.19
Profitability
-$1.75
-$18.38M
-9202.00%
-9202.00%
-53.86%
-32.16%
P/E Metrics
-2.45
-0.01
-0.01
Analyst Price Target & Rating
$5.00
$5.00
$5.00
2/5
4 Analysts
-71.80%
Financial Health Scores
-4.26
2/9
$70.75M
$85.83M
$8.3M
-$27.46M
Key Metrics (TTM)
-$23.04M
-76.81
0.87
11.88
-53.86%
-30.00%
-16.37%
-99.56%
-1420 days
Company Executives
| Name | Title |
|---|---|
| Martin Brenner | Chief Executive Officer, Chief Scientific Officer & Director |
| Felipe Duran | Chief Financial Officer |
| Marc Banjak | Chief Legal Officer |
| Cory Schwartz | Director of Research and Early Development |
Poll Results
No votes yet today — be the first to share your view!
About iBio, Inc. (NASDAQ:IBIO) Stock
iBio, Inc., a United States-based biotechnology firm, delivers contract development and manufacturing (CDMO) services to its collaborators and external clients. Its operations are structured into two distinct segments: Biopharmaceuticals and Bioprocessing. The company's leading therapeutic candidate, IBIO-100, is currently progressing through investigational new drug (IND) development, aimed at addressing systemic scleroderma and idiopathic pulmonary fibrosis. Additionally, iBio is engaged in the preclinical development of vaccine candidates, including IBIO-200 and IBIO-201, designed to prevent severe acute respiratory syndrome coronavirus 2. Another candidate, IBIO-400, is in development for the treatment of classical swine fever. Beyond its proprietary pipeline, iBio provides recombinant ... proteins to third parties, available both as catalog items and custom-synthesized products. It also offers comprehensive services spanning process development, advanced manufacturing, filling and finishing, and bioanalytical support. iBio maintains several strategic partnerships: a licensing agreement with Planet Biotechnology, Inc. for infectious disease therapeutics; a collaborative effort with The Texas A&M University System focused on COVID-19 vaccine candidates; a licensing pact with the University of Natural Resources and Life Sciences, Vienna; and a collaboration with CC-Pharming Ltd. Its corporate headquarters are situated in Bryan, Texas.
2026-08-04 07:00:00
SAN DIEGO, Aug. 04, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary diseases, today announced the appointment of Molly Carr, M.D., as Chief Medical Officer, further strengthening its executive leadership as the company advances its clinical-stage cardiometabolic pipeline. An experienced physician with over 30 years of clinical, academic and biopharmaceutical experience in endocrinology and metabolic disease, Dr. Carr will lead the company's global clinical strategy, medical affairs, and regulatory initiatives as it advances its pipeline toward late-stage development.
2026-07-01 07:00:00
Single-dose IBIO-610 achieved up to 98% inhibition of active Activin E through eight weeks, supporting a differentiated, long-acting antibody approach
iBio to Participate in Upcoming Healthcare Investor Conferences
2026-06-02 16:01:00
SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO) (“iBio” or the “Company”), an AI-driven innovator developing therapies for cardiometabolic, obesity and cardiopulmonary diseases, today announced that Martin Brenner, DVM, Ph.D., Chief Executive Officer and Chief Scientific Officer, and Felipe Duran, Chief Financial Officer, will participate in the Jefferies Global Healthcare Conference and the Leerink Partners Therapeutics Forum: I&I and Metabolism Conference.
2026-06-02 07:00:00
IBIO-600 is potentially best-in-class, long-acting anti-myostatin monoclonal antibody designed to preserve muscle and improve body composition
iBio Reports Q3 Fiscal Year 2026 Financial Results and Provides Corporate Update
2026-05-12 16:05:00
Received regulatory clearance to initiate its Phase 1 clinical trial of IBIO-600 in Australia Announced a strategic pipeline expansion into pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF) of its bispecific antibody Reported new preclinical data from its obese non-human primate (NHP) study evaluating IBIO-610, with visceral fat reduced by 6.7% and total fat mass by 5.2% SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator developing therapies for cardiometabolic, obesity and cardiopulmonary diseases, today reported financial results for the third quarter ended Mar. 31, 2026, and provided a corporate update on its progress. “This last quarter was marked by significant advancement across our full pipeline.
Frequently Asked Questions
-
What is the current iBio, Inc. (IBIO) stock price?
-
iBio, Inc.(NASDAQ:IBIO) stock price is $1.41 in the last trading session. During the trading session, IBIO stock reached the peak price of $3.82 while $0.57 was the lowest point it dropped to. The percentage change in IBIO stock occurred in the recent session was 1.44% while the dollar amount for the price change in IBIO stock was $0.02.
-
IBIO's industry and sector of operation?
-
The NASDAQ listed IBIO is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of IBIO?
-
Martin Brenner | Chief Executive Officer, Chief Scientific Officer & Director
Felipe Duran | Chief Financial Officer
Marc Banjak | Chief Legal Officer
Cory Schwartz | Director of Research and Early Development
| -
How many employees does IBIO have?
-
Number of IBIO employees currently stands at 20. IBIO operates from 11750 Sorrento Valley Road, San Diego, CA 92121, US.
-
Link for IBIO official website?
-
Official Website of IBIO is: https://www.ibioinc.com
-
How do I contact IBIO?
-
IBIO could be contacted at phone #979 446 0027 and can also be accessed through its website. IBIO operates from 11750 Sorrento Valley Road, San Diego, CA 92121, US.
-
How many shares of IBIO are traded daily?
-
The average number of IBIO shares traded daily for last 3 months was 960.55K.
-
What is the market cap of IBIO currently?
-
The market value of IBIO currently stands at $22.26M with its latest stock price at $1.41